Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales

Next Previous
Search
Trial Profile

A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
  • Indications Bacteraemia; Citrobacter infections; Enterobacter infections; Escherichia coli infections; Gram-negative infections; Klebsiella infections; Providencia infections; Serratia infections
  • Focus Therapeutic Use
  • Acronyms MERINO III

    • Most Recent Events

    • 07 Dec 2021 Planned initiation date changed from 1 Jan 2021 to 1 Jan 2022.
    • 07 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.
    • 22 Apr 2021 Planned initiation date changed from 1 Jun 2020 to 1 Jan 2021 , according to Trial design and protocol published in the Trials

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top